Mapp Biopharmaceutical

Mapp Biopharmaceutical was founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin to develop novel drugs for the prevention and treatment of infectious diseases, with a focus on unmet needs in global health and biodefense. The company has been developing Ebola treatments for more than a decade and has been collaborating with the U.S. and Canadian governments to advance this treatment.